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Received August 19, 2014; accepted June 16, 2015AbstractBackground: Our study sought to assess the effectiveness of a constant micropump infusion of atropine and pralidoxime chloride compared with
repeated-bolus doses in patients with severe acute organophosphorus insecticide poisoning (AOPP).
Methods: A total of 60 patients with severe AOPP, defined as cholinergic crisis with respiratory failure or cerebral edema, were randomly divided
into two groups of 30 patients each. In the experimental group, patients received a continuous micropump of atropine and pralidoxime chloride;
in the control group, patients were given intermittent injections of atropine and pralidoxime chloride. Primary outcome measures were the dose
of atropine required for atropinization, Acute Physiology and Chronic Health Evaluation II (APACHE II) score at atropinization, time to
atropinization and acetylcholinesterase (AchE) recovery time. Additionally, the case fatality rate was measured as a secondary outcome.
Results: Compared to patients in the control group, the time to atropinization, AchE recovery time, dose of atropine when atropinization
occurred, and APACHE II score in the experimental group showed a statistically significant therapeutic effect ( p < 0.05), and the case fatality
rate of the experimental group was lower than that of the control group ( p < 0.05).
Conclusion: Continuous micropump of atropine and pralidoxime chloride combined is more effective than the use of repeated-bolus injection in
the treatment of severe acute organophosphorus insecticide poisoning.
Copyright © 2015 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Acute organophosphorus insecticide poisoning (AOPP) is a
major cause of self-poisoning in developing countries,
responsible for the deaths of an estimated 200,000 people each
year.1 It is a common emergency accident in China with an
average mortality rate of 10%. Furthermore, severe AOPPConflicts of interest: The authors declare that there are no conflicts of interest
related to the subject matter or materials discussed in this article.
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1726-4901/Copyright © 2015 Elsevier Taiwan LLC and the Chinese Medical Assrapidly leads to acute cholinergic crisis and includes symp-
toms resulting from hyperstimulation of the central and pe-
ripheral muscarinic and nicotinic receptors. Death is usually
caused by respiratory failure resulting from paralysis of the
diaphragm and intercostal muscles and cerebral edema, with a
case fatality rate of up to 30%.2 The standard treatment for
AOPP is to give intravenous atropine and oximes.3 Treatment
with atropine is well established, which inhibits the effect of
acetylcholine at muscarinic receptors. It has been reported that
continuous micropump injection of atropine can significantly
reduce the case fatality rate of severe AOPP.4 Reactivation of
inhibited acetylcholinesterase (AchE) occurs after treatment
with oximes, such as pralidoxime chloride, and the minimum
concentration in plasma at which this treatment is effective isociation. All rights reserved.
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hours has been the standard regimen in Asian district hospi-
tals, but many clinicians remain unconvinced of its effective-
ness.5 Evidence suggests, however, that the concentration of
pralidoxime in the blood might need to be higher to antagonize
the toxic effects of many insecticides. Thus, a bolus-loading
infusion followed by a maintenance infusion may be the best
regimen. Because the study of continuous micropump infusion
of oxime in treating AOPP has rarely been reported,6 the effect
of a continuous micropump of atropine and pralidoxime
chloride combined in the treatment of severe AOPP has not
been tested. In the current study, we aimed to assess the
effectiveness of a constant micropump infusion of atropine
and pralidoxime chloride compared with repeated-bolus doses
in patients with severe AOPP.
2. Methods2.1. PatientsPatients were enrolled in our study from July 2007 until
May 2012. A total of 60 patients received a diagnosis of severe
AOPP based on a history of oral consumption of organo-
phosphorus insecticide, the presence of characteristic signs of
acute cholinergic crisis (in particular: sweating, pinpoint pu-
pils, urinary and fecal incontinence, bronchorrhoea, broncho-
spasm, and hypotension) with respiratory failure or cerebral
edema, and plasma erythrocyte AchE activity less than 30% of
normal. Exclusion criteria consisted of patients who received
cardiopulmonary resuscitation during emergency admission,
the presence of chronic disease such as heart and lung disease,
and concomitant ingestion of other toxicants. Sixty patients
with severe AOPP were randomly divided into a continuous
micropump atropine and pralidoxime chloride group (experi-
mental group) and an intermittent injection of atropine and
pralidoxime chloride group (control group).
This research was approved by the Ethics Committee of
The Songjiang Central Hospital and was undertaken in
accordance with the principles of the Declaration of Helsinki.2.2. Treatment
2.2.1. General supportive treatment
All patients with AOPP were assessed and resuscitated in
the emergency room before admission to the intensive care
unit. Sixty patients received intratracheal intubation and me-
chanical ventilation in order to maintain airway patency and
ensure adequate arterial oxygen saturation. According to the
standard treatment plan in China,7e9 gastric lavage with
20,000 mL of warm water was immediately performed after
intubation until the returning fluid was clear and odorless.
After gastric lavage, crushed tablets of activated charcoal were
left in the stomach and replaced every 8 hours for the next 48
hours. Meanwhile, every patient also received supportive
treatment such as hepatoprotection (daily 1.8 g of reduced
glutathione), rehydration, diuresis, and hemoperfusion (run
immediately after admission, 2 hours daily for 2 days).Patients were monitored continuously by noninvasive means to
measure their blood pressure, heart rate, respiratory rate, and
arterial oxygen saturation.
2.2.2. Specific antidotal treatment
Every patient was given an initial loading dose of 20 mg of
atropine and 2 g of pralidoxime chloride intravenously.8,10
After the loading dose of atropine and pralidoxime chloride
was administered in the experimental group, a continuous
micropump atropine infusion was set up at a speed of 20 mg/
hour to keep the patient atropinized without reaching toxic
levels, using frequent adjustments of dose (usually adjusting
the dosage every 5 minutes with the rate of 2 mg/hour
declining according to the clinical symptoms of patient).
When the patient achieved most of (at least 4 out of 5) the
target endpoints11 (i.e., heart rate > 80 beats/minute, dilated
pupils, dry axillae, systolic blood pressure >80 mmHg, clear
chest with absence of wheeze) for atropine therapy, an intra-
venous infusion of the minimum dose of atropine was main-
tained. Meanwhile, a continuous micropump of pralidoxime
chloride infusion was also set up at a speed of 8 mg/kg/hour10
until the AchE value recovered to 60% of normal.
In the control group, a subsequent dose of 5 mg of atropine
injection every 10 minutes was given until atropinization was
achieved. Patients also received an intravenous dose of 1 g of
pralidoxime chloride every 6 hours until the AchE value
recovered to 60% of normal.
2.2.3. Outcomes
The primary outcomes were the atropine dose needed for
atropinization, the time to atropinization, the time to AchE
recovery, and the Acute Physiology and Chronic Health
Evaluation II (APACHE II) score at atropinization. Case fa-
tality rate in the whole hospitalization period was considered a
secondary outcome.2.3. Statistical analysisAll analyses were performed using SPSS 11.0 software
(SPSS Inc, USA). Continuous variables were investigated for
departure from normality by use of the ShapiroeWilk test. For
the normally distributed data, we calculated the mean differ-
ence and performed Student t tests to compare the experi-
mental group and the control group. For the skewed data, we
performed nonparametric ManneWhitney U tests to investi-
gate differences between the two groups. The significance of
the case fatality rate difference between two groups was
determined by a Chi-square test, and p < 0.05 was used to
determine statistical significance.
3. Results
There were a total of 60 patients including 28 men and 32
women with a mean age of 32.5 years, and an age range of
14e56 years. Among the 60 cases of poisoning, there were 18
cases of methamidophos, 17 cases of omethoate, 11 cases of
dichlorvos, 5 cases of trichlorfon, and 9 cases of composite
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phosphorus insecticides was 50 mL (range 20e100 mL), and
the time interval between exposure and admission to the
hospital ranged from 30 minutes to 2 hours. There was no
statistically significant difference in sex and age, organo-
phosphorus insecticide composition, time interval between
exposure and admission to hospital, and AchE activity after
poisoning between the two groups (Table 1).
Table 2 shows that continuous micropump of a combined
atropine and pralidoxime chloride infusion was a greater
benefit to patients with severe AOPP than the intermittent
injections of atropine and pralidoxime chloride given to the
control group. During the course of treatment, the time to
atropinization and time to AchE recovery was shorter in the
experimental group than the control group, leading to a lower
amount of intravenous atropine needed for atropinization
given to the experimental group than to the control group. The
APACHE II score at atropinization was also significantly
better in the experimental group than in the control group.
Compared with that in the control group, there was a lower
case fatality rate (10% vs. 26.7%) in patients given a micro-
pump infusion of atropine and pralidoxime chloride.
4. Discussion
AOPP accounted for more than 70% of the total number of
insecticide poisonings in China, ranking first in acute chemical
poisoning among adult Chinese. Oral administration of largeTable 1
Baseline characteristics of the two treatment groups.
Baseline characteristics Control (n ¼ 30)
Men (n) 15
Age (y) 32.53 ± 10.02
Types of poisons
Methamidophos 9 (30)
Omethoate 9 (30)
Dichlorvos 5 (16.7)
Trichlorfon 3 (10)
Composite organophosphorus 4 (13.3)
Volume of poisons (mL) 49.66 ± 24.24
Time to hospital after exposure (h) 1.21 ± 0.44
AchE level (U/L) 19.83 ± 8.35
Intubated during resuscitation 30 (100)
Data are expressed as mean ± standard deviation or n (%).
Reference value for acetylcholinesterase (AchE; colorimetric method): 130e310U
AchE ¼ acetylcholinesterase.
Table 2
Outcome comparison of the two treatment groups.
Group n Atropinization
(min)
AchE recovery (d)
Experimental 30 49.3 ± 26.5 3.5 ± 0.8
Control 30 64.5 ± 29.5 5.8 ± 0.4
t or X2 2.09 14.08
p < 0.05 < 0.05
Data are presented as mean ± standard deviation.
AchE ¼ acetylcholinesterase; APACHE ¼ Acute Physiology and Chronic Health
a ¼ X2.doses of organophosphorus insecticides can cause severe
AOPP, because of the rapid inhibition of AchE activity, lead-
ing to the accumulation of acetylcholine at cholinergic syn-
apses. The excess acetylcholine causes constant acetylcholine
receptor triggering, resulting in serious muscarinic, nicotinic,
and central nervous system symptoms, and is life threat-
ening.12 Therefore, finding ways to improve the survival rate
of severe AOPP is an important concern for emergency and
critical care workers.
Currently, there is a consensus that comprehensive mea-
sures for treating severe AOPP consisting of the administration
of muscarinic antagonists (usually atropine) and oximes
(usually pralidoxime) are specific antidotes for organophos-
phorus insecticide poisoning. Early administration of sufficient
doses of atropine may create conditions for oximes to play a
more substantial role. Pralidoxime chloride can be highly
effective in restoring skeletal muscle strength and improving
diaphragmatic weakness where atropine has virtually no ef-
fect.13 In actual clinical work, atropine has some features such
as the ability to be quickly effective, a short half-life, and a
rapid metabolism. However, residual organophosphorus in-
secticides are stored in fat tissue and continue to be released
into circulation. Therefore, the amount of atropine can sud-
denly appear inadequate or excessive, leading to a variety of
clinical manifestations, making it difficult to control the dose
of atropine. It is worth noting that insufficient dosage, exces-
sive reduction, or premature withdrawal of atropine can cause a
rebound in symptoms. At the same time, there is a tendency toExperimental (n ¼ 30) p
13 > 0.05
32.46 ± 10.06 > 0.05
9 (30) > 0.05
8 (26.7) > 0.05
6 (20) > 0.05
2 (6.6) > 0.05
5 (16.7) > 0.05
50.16 ± 24.26 > 0.05
1.22 ± 0.39 > 0.05
20.5 ± 7.46 > 0.05
30 (100) > 0.05
/L.
Atropine dose for
atropinization (mg)
APACHE II
score
Case fatality
rate (%)
40.3 ± 6.0 10.2 ± 2.0 10.0
53.5 ± 7.3 19.3 ± 6.0 26.7
4.43 7.88 13.11a
< 0.05 < 0.05 < 0.05
Evaluation; X2 ¼ Chi square value.
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toxicity can result in agitation, confusion, hyperthermia, and
severe tachycardia.14 It has been reported that 10.78% of
mortality was due to atropine poisoning in the analysis of 1403
cases of organophosphorus insecticide poisoning deaths in
China.15 Consequently, close observation and dose adjustment
are essential to avoid both under- and over-atropinization.
Pralidoxime chloride has a short half-life of 1.0e1.5 hours.
If treatment with oximes is delayed by 2 hours, the phosphate
bound to the inhibited AchE loses an alkyl group and becomes
resistant to pralidoxime therapy.16 In addition, high doses of
pralidoxime chloride administration can inhibit AchE, result-
ing in respiratory arrest.17 Therefore, it is essential to explore
the rational and effective use of the treatment in order to
maintain an appropriate balance of treatments.
In the current study, we have reported that a continuous
micropump of atropine and pralidoxime chloride combined
reduced the amount of atropine needed for atropinization, time
to atropinization, and time to AchE recovery compared to an
intermittent injection regimen. Thus, the number of deaths was
also reduced in the experimental group. Therapy requires
immediate administration of sufficient atropine to reverse
signs of cholinergic excess together with airway and ventila-
tory support. Current guidelines recommend the use of bolus
doses to attain atropinization, followed by an infusion.18 In our
study, we administered a continuous micropump of atropine
infusion at a speed of 20 mg/hour after the loading dose was
provided in the experimental group.19 The amount adminis-
tered was similar to the hourly dosage of atropine used in the
control group in order to reduce research bias. The experi-
mental treatment was shown to be beneficial for avoiding both
underatropinization and overatropinization due to close
observation and dose adjustment. The current data showed that
the time to atropinization and dosage of atropine used were
more optimal in the continuous micropump infusion group
than in the control group, suggesting the importance of
achieving early atropinization and maintaining a stable plasma
atropine concentration in the treatment of organophosphate
insecticide poisoning.
To our knowledge, the exact role of pralidoxime in treat-
ment of AOPP remains a matter of debate. It has been reported
that two small uncontrolled case series suggested that prali-
doxime could have a possible benefit if given according to the
World Health Organization dosage regimen.5 By contrast, two
meta-analyses concluded that pralidoxime causes harm such as
increased the risk of death and incidence of intermediate
syndrome.20,21 A systematic review reported that there was
insufficient evidence to establish the effectiveness of oximes in
AOPP.22
A randomized controlled trial including 200 patients with
moderately severe AOPP showed reduced mortality in patients
treated with continuous pralidoxime infusion (1 g/hour for 48
hours after a 2 g loading dose) compared to repeated-bolus
injection.23 It is the first known trial of dosing oximes as
recommended by the World Health Organization, using a dose
of 8 mg/kg/hour of pralidoxime after a loading dose of 2 g.10
Similar to the aforementioned research, our data also supportthe efficiency of continuous micropump pralidoxime chloride
and atropine infusion in treating severe AOPP. Compared to
the traditional method of intermittent intravenous administra-
tion, the use of a continuous micropump intravenous antidote
not only maintains the effective drug concentration in circu-
lation, but also is conducive to the observation of disease
changes. This leads to a stable state of atropinization for pa-
tients with severe AOPP, therefore avoiding atropine overdose.
We also demonstrated that the APACHE II score, which is
commonly used to assess the severity of critically ill patients,
was better in the experimental group than in the control group
during atropinization, strongly indicating that sustained and
effective drug maintenance is an important means to stabilize
the progression of the disease. It is worth mentioning that a
randomized controlled trial, which was performed in Sri
Lanka, was reported in 2009 to compare the World Health
Organization-recommended regimen of pralidoxime to a pla-
cebo in the treatment of AOPP.24 No evidence was found that
this regimen improved survival or reduced the need for intu-
bation in patients with organophosphorus insecticide
poisoning. However, there were two key differences from our
study. First, the median time from organophosphorus insecti-
cide ingestion to hospital in that study was 4.4 hours, signif-
icantly longer than the 1.2 hours in our study. Second, only
17.4% of cases were intubated in that study, compared to
100% in our study. There was a trend toward worse outcomes
in patients not intubated before pralidoxime administration,
suggesting that intubation may be protective against adverse
effects such as respiratory arrest. In contrast, we believe that
an earlier application of pralidoxime chlorine and strong
supportive therapy is necessary for our regimen to play the
biggest role in the treatment of severe AOPP.
This study had several limitations. First, the number of
patients was small. The minimum sample size calculated for
each group was 50 (one-sided significance level of 5%, power
80%, a 20% difference of mortality between two groups). It is
relatively difficult to include more patients with severe AOPP
due to the relatively high level of civilization in the Shanghai
area. It should be noted that the results of the current study
provide evidence that the method of micropump infusion of
atropine and pralidoxime chloride may be the better choice for
treatment of severe AOPP. However, more cases are required
in the future to better support the aforementioned results.
Second, we are unable to assess the relationship between
plasma atropine and/or pralidoxime concentrations and the
study outcomes because those concentrations are not measured
in this study. Third, we did not measure serum/urine concen-
trations of organophosphorus insecticide. Moreover, we did
not conduct a comprehensive toxicological screen to
completely exclude the possibility of concomitant toxicant
exposure. Therefore, although all patients in this study had a
clear history and overt manifestations of acute organophos-
phorus insecticides poisoning, there remains a possibility of
exposure misclassification. The aforementioned limitations
shall be evaluated in future research.
In conclusion, the method of continuous micropump infu-
sion of atropine and pralidoxime chloride after a loading dose
713H.-X. Liu et al. / Journal of the Chinese Medical Association 78 (2015) 709e713is considered to be an effective strategy in the treatment of
severe AOPP. This is due to its ease of operation, precise
control of speed, and dose of antidote into patients, fast time to
reach atropinization, a shortening of the AchE recovery time,
and a significant reduction in the case fatality rate. Because
our study incorporated a small sample size, we believe that
further multicenter trials are required to provide clearer evi-
dence supporting the efficacy of the continuous infusion of
drugs in patients with severe AOPP.
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